Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05092009 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lung Cancer Organoids and Patient Derived Tumor Xenografts

Study acronym: IPON-3
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 13, 2026 (before its estimated October 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Apr 1, 2026 to Oct 1, 2026 Trial status: Recruiting to Active, Not Recruiting · Site details revised at 3 of 3 sitesv8 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
  2. Re-verified, no change to tracked fieldsv7
  3. Primary completion date: Apr 1, 2024 to Apr 1, 2026 Completion date: Apr 1, 2025 to Apr 1, 2028v6 Show 1 more changeShow less
    • Completion date: Apr 1, 2025 to Apr 1, 2028
  4. Primary completion date: Apr 1, 2023 to Apr 1, 2024v5
  5. Start date changed from estimate of Sep 1, 2022 to Oct 5, 2022v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting Start date: Apr 1, 2022 to Sep 1, 2022 · Site details revised at 3 of 3 sitesv3 Show 2 more changesShow less
    • Start date: Apr 1, 2022 to Sep 1, 2022
    • Site details revised at 3 of 3 sites
  2. Start date: Nov 1, 2021 to Apr 1, 2022 Primary completion date: Nov 1, 2022 to Apr 1, 2023 · Completion date: Nov 1, 2024 to Apr 1, 2025v2 Show 2 more changesShow less
    • Primary completion date: Nov 1, 2022 to Apr 1, 2023
    • Completion date: Nov 1, 2024 to Apr 1, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Extra tissue will be taken from patient during a procedure in standard of care. Also, through an existing line, 10ml of extra blood will be drawn. From this material the investigator will try to establish matched normal and primary human lung cancer organoids.
Trial Details
NCT Number NCT05092009
Lead Sponsor Maastricht Radiation Oncology
Conditions Lung Cancer
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov